To clarify the roles of these pathways in EHMT2-mediated EGFR-TKI resistance, we determined p-AKT, AKT, β-Catenin, YAP, and actin expression levels in the indicated resistant NSCLC cell lines, which were treated with or without UNC0638. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.